NASDAQ : ETRA

Electra Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 8.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 508.41M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.

Details

NameElectra Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees46
Founded2018
Ipo Date2026-09-18
CeoQuehuong Dong
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price15.00
IsinUS2848251060
Cusip284825106
Cik2088082
Sic2836
Stock TypeCommon Stock

Key executives

NameTitle
Quehuong (Kathy) Dong, Pharm.D., M.B.A.President, Chief Executive Officer, Director
Chris Clark, C.F.A.Chief Financial Officer
Kim-Hien Dao, D.O., Ph.D.Chief Medical Officer
Gary S. Koe, Ph.D.Chief Technical Officer
Graham Parry, Ph.D.Chief Scientific Officer
Nancy Stagliano, Ph.D.Chairperson
Matthew Fust, M.B.A.Director
Thomas Geninatti, Ph.D.Director
Carl L. Gordon, Ph.D., C.F.A.Director
Beth Seidenberg, M.D.Director

Contact

Address230 E Grand Avenue, Suite S-100, South San Francisco, California 94080, United States
Phone(888) 743-2290
Websitehttps://electra-therapeutics.com